QUALIFICATIONS PROFILE

Highly motivated, results-driven, and broad-based years of experience in new product planning, licensing management, and strategic business development within biomedical and life science arena. Exhibit superior talents in creating effective marketing strategies and plans to increase sales, capitalize on growth opportunities, and maintain profitable business operations. Known as an empowering manager adept at fostering team unity toward fulfillment of corporate target goals. Excel at establishing win-win relationships and addressing diverse customer needs by providing innovative solutions and ensuring utmost satisfaction. Proven effectiveness in a fast-paced environment with dedication to superior service. Bilingual in English and Mandarin. U.S. Permanent Residence: Green Card Holder.

CORE STRENGTHS

Business Management and Operations Market Due Diligence

Strategic Sales Action Plans Development Quality Assurance and Regulatory Compliance

Competitive Market Research and Analysis Business Model Building

Problem Resolution and Decision Making Outstanding Customer Service and Relations

Superior Interpersonal and Communication Skills Excellent Presentation and Negotiation Abilities

EMPLOYMENT HISTORY

ELI LILLY & CO. 2010–PRESENT

New Product Planning, Neuroscience, Indianapolis, IN Mar 2012–Present

Assume full responsibility in handling depression, bipolar depression, schizophrenia, and insomnia therapeutic areas within the Neuroscience NPP team

Preside over the NPP Market Research, Payer Reimbursement Access, Global Strategic Pricing, Forecasting, and Global Health Outcomes

Vigorously participate in Core Team meetings to provide strategic guideline for early phase assets

Instrumental in outlining marketplace landscape (patient, payer, physician) and creating Draft Launch Labels

Maintain frequent interaction with the US, ACE, and Japan affiliates to ensure pipeline clarity

Play a vital role in shallow/deep dives from the Global perspective to capture market understanding

Sales Representative Relief, Diabetes, Guangzhou, China Oct 2011–Feb 2012

Built and maintained long-term quality relationships with physicians in public and military hospitals, office staffs and others in the patient care continuum

Planned and coordinated territory program, group selling and conducted academic journal clubs

Masterfully led all initiatives to foster positive working environment, grow market share, and improve sales performance in the territory

MBA Summer Intern, Global Strategic Pricing, Indianapolis, IN Jun 2010–Sep 2010

Meticulously evaluated pricing strategy and identified potential opportunities to optimize market value for insulin

Conceptualized and implemented effective marketing strategic plan for diabetic market in major Europe, Australia, Canada and China

Executed reimbursement and market access due diligence

Generated approximately $200M by developing strategic branding and pricing

SELF-EMPLOYED 2009–2011

CytoScale Diagnostics, LLC., Los Angeles, CA Sep 2009–Aug 2011

Drove all efforts to develop business plan for financing and commercializing the project of Nano-tech based cancer detector developed by UCLA NanoSystems Institute (CNSI), Institute for Molecular Medicine (IMED)

Secured $7M partnership and led the negotiation with China pharmaceutical industrial investors in manufacture and commercial distribution

Grand Oncology, Inc., Shanghai, China Jun 2009–Oct 2011

Displayed unsurpassed expertise in managing a team of 6 in development of business plan for chain Radiation Oncology Clinics in China

Primarily held responsible for strategic marketing, medical/FDA regulations, insurance policy, business model building and operation

Honored and won 1st place in BPD competition, thus successfully securing $7M for company startup

TIANJIN ZHONGXIN PHARMACEUTICAL CORP. LTD 1998–2004

International Business Development, China Aug 1998-–Jan 2004

Exampled outstanding abilities to establish partnership with U.S. Sicor biotech

Singlehandedly managed all facets of evaluation, market intelligence and negotiation that led to acquisition of phase I recombinant α-2b interferon for hepatitis B from Lithuania R&D institute; $ 2M upfront license-in

Directed and coordinated business model building, which led to joint-venture “Hualida Biotech” and milestone payment of $ 45M

Solidified productive relationships with Luxemburg Orchid investor

Utilized strong negotiation skills leading to license-in phase I Astragalus polysaccharide developed by U.S. Pharmacogenesis

Secured $20M upfront and led business model building, which led to joint-venture setup, Cinorcoh Pharma and $ 40M milestone payment

Applied dynamic leadership talents in the evaluation, business model and stock share negotiation, which led to license-in Cephalosporin series antibiotic product line with South Korean Sinpoon Pharma group; $20M upfront and $ 35M milestone for JV setup, Sinpoon Pharma (Tianjin).

Carried out on-site inspection in overseas investment evaluation with Egyptian Pharma Holding

Seamlessly negotiated business model of JV in Egypt earning $20M upfront, license out of 3 products (Cardio Angina, Influenza and hepatitis B) for manufacture and exclusive marketing in Egypt

Internal GMP Advisor Jun 2001–Dec 2003

Supervised daily activities of a team of 6 in $100M new facility construction at Tech. and Econ. Develop. Area (TEDA) and subsidiary facility relocation

Oversaw contracted engineering design, led selection and purchasing of manufacturing machinery, negotiated price and contract, and managed installation and qualification process

Conducted onsite GMP inspecting simulation for 5 portfolio factories, consulted GMP compliance and supervised 5 onsite GMP auditions by FDA (USA), TGA (Australia) and SOS (UK)

Board Meeting Coordinator Jun 2000–Dec 2003

Communicated with internal and external executive directors in Sino-foreign pharmaceutical JVs for strategic pipeline planning, budgeting, market planning and integration strategy decisions

Rendered high level of assistance to the CEO and Chairman in organizing annual board meetings for Sino-foreign JVs

Participated in technical and business discussion at executive level

Gained comprehensive experience to executive management of both Chinese pharmaceutical industry and multinational pharmaceuticals

EDUCATION

MASTER OF BUSINESS ADMINISTRATION (MBA), MAJOR IN MARKETING AND INVESTMENT

UCLA Anderson School of Management, Los Angeles, CA: June 2011

POSTDOCTORAL RESEARCH ASSOCIATE

Texas A&M Health Science Center, College of Medicine, College Station, TX: Jan 2009–Aug 2009

Collaborated PI in secure of $1.4M NIH fund; Initiated liaison partnership and developed business plan of $5M fund raising for a potential dry form of age-related macular degeneration (AMD) drug developed by TAM Health Science Center

DOCTOR OF PHILOSOPHY (PH.D.) IN BIOMEDICAL SCIENCE (NEUROSCIENCE-NEUROPHARMACOLOGY)

Texas A&M Health Science Center, College of Medicine, College Station, TX: Jan 2004–Dec 2008

Led research of CNS GABAergic synaptic genesis and degeneration in learning and memory ability in early development and aging stages of life.

BACHELOR OF SCIENCE IN (BS) PHARMACY

Shenyang Pharmaceutical University, Shenyang, China: Sep 1993–Jul 1998

PROFESSIONAL AFFILIATIONS

Member, UCLA Anderson Healthcare Business Association (HBA); UCLA Anderson Marketing Association; UCLA Anderson Investment Finance Association (IFA); Member of UCLA Anderson Alumni Network; Healthcare Panel Manager of Greater China Business Associations (GCBA) & Wilbur. K. Woo Conference

Overseas editor for the Journal of Chinese Herbal Medicine: 2009–Present

Member, Sino-American Biopharmaceutical Professional Association (SABPA)

Member, Society of Neuroscience (SfN)

Member, Association of Pharmacology and Experimental Therapeutics (ASPET)

Contact this candidate